Saul Dominik, Menger Maximilian M, Ehnert Sabrina, Nüssler Andreas K, Histing Tina, Laschke Matthias W
Department of Trauma and Reconstructive Surgery, Eberhard Karls University Tübingen, BG Trauma Center Tübingen, 72076 Tübingen, Germany.
Kogod Center on Aging and Division of Endocrinology, Mayo Clinic, Rochester, MN 55905, USA.
Bioengineering (Basel). 2023 Jan 9;10(1):85. doi: 10.3390/bioengineering10010085.
Bone healing is a multifarious process involving mesenchymal stem cells, osteoprogenitor cells, macrophages, osteoblasts and -clasts, and chondrocytes to restore the osseous tissue. Particularly in long bones including the tibia, clavicle, humerus and femur, this process fails in 2-10% of all fractures, with devastating effects for the patient and the healthcare system. Underlying reasons for this failure are manifold, from lack of biomechanical stability to impaired biological host conditions and wound-immanent intricacies. In this review, we describe the cellular components involved in impaired bone healing and how they interfere with the delicately orchestrated processes of bone repair and formation. We subsequently outline and weigh the risk factors for the development of non-unions that have been established in the literature. Therapeutic prospects are illustrated and put into clinical perspective, before the applicability of biomarkers is finally discussed.
骨愈合是一个多方面的过程,涉及间充质干细胞、骨祖细胞、巨噬细胞、成骨细胞、破骨细胞和软骨细胞,以修复骨组织。特别是在包括胫骨、锁骨、肱骨和股骨在内的长骨中,这一过程在所有骨折中约有2%至10%会失败,给患者和医疗系统带来毁灭性影响。这种失败的潜在原因是多方面的,从缺乏生物力学稳定性到生物宿主条件受损以及伤口内在的复杂性。在这篇综述中,我们描述了参与受损骨愈合的细胞成分,以及它们如何干扰精心编排的骨修复和形成过程。随后,我们概述并权衡了文献中已确定的骨不连发生的风险因素。在最后讨论生物标志物的适用性之前,阐述了治疗前景并将其置于临床背景中。